Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia
(Rockefeller University Press) Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 17, 2018 Category: Biology Source Type: news

Leukemia: Five easily overlooked signs you have the condition
LEUKEMIA, or blood cancer, symptoms are not always easily detected. The condition has several forms including acute myeloid leukaemia and chronic leukemia. You should look out for these five symptoms of the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 10, 2018 Category: Consumer Health News Source Type: news

New CAR T case study shows promise in acute myeloid leukemia
(H. Lee Moffitt Cancer Center& Research Institute) According to a case study from trial published online ahead of print in the journal Haematologica, a patient has remained cancer free for nine months after being treated with CYAD-01, followed by a bone marrow transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Quizartinib is the first FLT3 inhibitor to demonstrate improved overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations, a very aggressive form of the disease associated with poo... Biopharmaceuticals, Oncology Daiichi Sankyo Company, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2018 Category: Pharmaceuticals Source Type: news

Leukemia protective role of Y chromosome gene discovered
(Wellcome Trust Sanger Institute) Scientists have discovered the first leukemia protective gene that is specific to the male-only Y chromosome. Researchers at the Wellcome Sanger Institute and the University of Cambridge found that this Y-chromosome gene protects against the development of acute myeloid leukemia (AML) and other cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 7, 2018 Category: Biology Source Type: news

Novel pathway identified in development of acute myeloid leukemia with poor prognosis
(National University of Singapore, Yong Loo Lin School of Medicine) NUS researchers have discovered a new pathway by which a severe form of acute myeloid leukemia (AML) develops. The main player in the pathway, a protein called SHARP1, promotes leukemia development and maintenance, both on its own and through its actions on other genes. The discovery could lead to the development of novel SHARP1-specific treatments for this difficult-to-treat form of AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 24, 2018 Category: Biology Source Type: news

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
TOKYO, April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 23, 2018 Category: Drugs & Pharmacology Source Type: news

BIDMC-lead team develops new approach to study long non-coding RNAs
(Beth Israel Deaconess Medical Center) In a groundbreaking paper, investigators at the Cancer Research Institute Beth Israel Deaconess Medical Center developed a novel approach to identify and determine the functional role of lncRNAs relevant to chemotherapy resistance in Acute Myeloid Leukemia (AML). The new technique integrates information from publicly-available pharmacological data bases with leading-edge CRISPR technologies to screen for both coding and non-coding genes that influence response to treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2018 Category: Cancer & Oncology Source Type: news

Implications of Mutation Profiling in Myeloid Malignancies —PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Acute Myeloid Leukemia Hematologic Malignancies Myelodysplastic Syndromes Oncology Journal Review Article Source Type: news

Novel Drug Shows Promise Against Acute Myeloid Leukemia
April 11, 2018—(BRONX, NY)—In a study published online today in Science Translational Medicine,Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway atMontefiore Health System. (Source: Einstein News)
Source: Einstein News - April 11, 2018 Category: Universities & Medical Training Source Type: news

Novel drug shows promise against acute myeloid leukemia
(Albert Einstein College of Medicine) In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: news

Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176 THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's ...
Source: Amgen News Release - April 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Molecular Minimal Disease in Remission Predicts AML Relapse
WEDNESDAY, March 28, 2018 -- The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia (AML), according to a study published in the March 29 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2018 Category: Pharmaceuticals Source Type: news

Childhood Acute Myeloid Leukemia (AML)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 23, 2018 Category: General Medicine Source Type: news

Huntsman Cancer Institute joins national clinical trial targeting AML
(Huntsman Cancer Institute) Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia& Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2018 Category: International Medicine & Public Health Source Type: news

Targeting Cholesterol Pathway Shows Potential for AML Treatment
Researchers have discovered that AML cells require high levels of cholesterol for survival, so the cholesterol pathway could represent a potential therapeutic option for the disease. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Myeloid Leukemia Hematologic Malignancies News Source Type: news

Study Demonstrates a Common Genetic Etiology for LCH, AML, and MF
Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Blood Disorders Hematologic Malignancies News Source Type: news

Girl, 10, was separated from her twin while she battled cancer
Amelia Wilson, from Billingham, County Durham, was first diagnosed with acute myeloid leukaemia in September 2015 and endured months of grueling chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2018 Category: Consumer Health News Source Type: news

Leukaemia symptoms - what is the aggressive blood cancer acute myeloid leukaemia?
LEUKAEMIA symptoms include pale skin and tiredness. These are the signs of the aggressive blood cancer that kills almost 5,000 people a year in the UK. (Source: Daily Express - Health)
Source: Daily Express - Health - February 27, 2018 Category: Consumer Health News Source Type: news

A mother Googled her toddler ’ s symptoms — and believes it may have saved the child ’ s life
It was a headline that captured her attention: “Boy, 13, died just A WEEK after being diagnosed with leukemia despite having NO symptoms beforehand.” Laura Handley, a mother of five, had been scrolling through Facebook when she was sucked into a story about a seemingly healthy 13-year-old boy who had died suddenly from an aggressive form of cancer called acute myeloid […]Related:Here’s what you should know about the flu season this yearFlu cases fall for the first time this awful influenza seasonCDC seeks new labs for bioterror pathogens to replace aging facility (Sour...
Source: Washington Post: To Your Health - February 24, 2018 Category: Consumer Health News Source Type: news

EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Acute Myeloid Leukemia Overview Video Acute Myeloid Leukemia Overview Video
This video discusses the pathophysiology and major clinical signs and symptoms of acute myeloid leukemia.Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2018 Category: Consumer Health News Tags: Med Students Commentary Source Type: news

New strategy to target transcription factor STAT5 to combat leukaemia
(University of Veterinary Medicine -- Vienna) Acute myeloid leukaemia is the most common type of acute cancer of the blood and bone marrow in adults. AML progresses quickly and only 26 percent of the patients survive longer than 5 years as resistance against established treatments arises. The most common molecular cause is FLT3 mutations, which result in hyper-activation of STAT5. A researcher consortium now reports on an early preclinical development to target STAT5 directly, which cooperates well with existing therapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 22, 2018 Category: Biology Source Type: news

Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes
Contrary to initial reports, romiplostim treatment of thrombocytopenia does not appear to increase the risk of progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Quiz: Molecular Risk Stratification in Acute Myeloid Leukemia
Test your knowledge in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - February 1, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Hematologic Malignancies Quiz Source Type: news

Enasidenib Can Cause Serious Symptoms in Some With Leukemia Enasidenib Can Cause Serious Symptoms in Some With Leukemia
A substantial minority of patients with relapsed or refractory acute myeloid leukemia (AML) show potentially deadly symptoms after treatment with enasidenib, according to a new analysis of data from an open-label trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Agios lines up another potential FDA nod with new leukemia drug
Less than five months after getting its first cancer drug approved, Cambridge-based Agios Pharmaceuticals has lined up another potential FDA nod — and the first for a medicine that it fully owns. Agios (Nasdaq: AGIO) said Tuesday that it had submitted an application for ivosidenib, a potential drug for patients with acute myeloid leukemia who have a specific genetic mutation, and whose cancer has relapsed or isn’t responding to initial treatment. The company said it had asked the FDA to review… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 26, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Your NEJM Group Today: Ecthyma Gangrenosum Image / Tranexamic Acid & Epistaxis / Arizona Family Med Opportunity
Check out today's selections from NEJM Group: NEJM Clinical Practice Center: Image in Clinical Medicine: A 21-year-old woman with acute myeloid leukemia who... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 12, 2017 Category: Primary Care Source Type: news

Immunotherapy strategy could be beneficial for relapsed acute myeloid leukemia
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers will present preliminary results from an ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on Saturday, Dec. 9. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2017 Category: Cancer & Oncology Source Type: news

Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
CIRM grant will support further development of Forty Seven Inc.'s CD47 antibody Hu5F9-G4 in an ongoing second trial for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome MENLO PARK, Calif., Dec. 6, 2017 -- (Healthcare Sales & Marketin... Biopharmaceuticals, Regenerative Medicine, Oncology Forty Seven, acute myeloid leukemia, Myelodysplastic Syndrome, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news

State's stem cell agency awards nearly $8 million for new leukemia therapies
(University of California - San Diego) The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine unanimously approved yesterday two grants worth a total of almost $8 million to University of California San Diego School of Medicine researchers investigating novel stem cell-based treatments for acute myeloid leukemia or AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2017 Category: Cancer & Oncology Source Type: news

The target landscape of clinical kinase drugs
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug mechanism of action. Using chemical proteomics, we analyzed the target spectrum of 243 clinically evaluated kinase drugs. The data revealed previously unknown targets for established drugs, offered a perspective on the "druggable" kinome, highlighted (non)kinase off-targets, and suggested potential therapeutic applications. Integration of phosphoproteomic data refined drug-affected pathways, identified response markers, and strengthened rationale for combination tr...
Source: ScienceNOW - November 30, 2017 Category: Science Authors: Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., Zecha, J., Reiter, K., Qiao, H., Helm, D., Koch, H., Schoof, M., Canevari, G., Casale, E., Depaolini, S. R., Feuchtinger, A. Tags: Cell Biology, Medicine, Diseases r-articles Source Type: news

Unforeseen new drug target discovered for acute myeloid leukemia
(Wellcome Trust Sanger Institute) A study reported in Nature has found an unexpected new drug target for acute myeloid leukemia that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers from the Wellcome Trust Sanger Institute, the Gurdon Institute and their collaborators show that inhibiting the METTL3 gene destroys AML cells without harming non-leukemic blood cells and reveals why METTL3 is required for AML cell survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2017 Category: Cancer & Oncology Source Type: news

Are You Sure That's What the Doctor Said About Your Leukemia?
Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Talking With Your Doctor (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 3, 2017 Category: Consumer Health News Source Type: news

Are You Sure That's What the Doctor Said About Your Leukemia?
THURSDAY, Nov. 2, 2017 -- The stress of a frightening leukemia diagnosis may impede clear doctor-patient communication, a new study suggests. Patients undergoing chemotherapy treatment for acute myeloid leukemia (AML) tend to view their illness and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2017 Category: General Medicine Source Type: news

Papers of note in Science Translational Medicine 9 (413)
This week’s articles describe new therapeutic targets for pulmonary arterial hypertension, acute myeloid leukemia, and Friedreich’s ataxia. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 31, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Blocking key pathways is a way to defeat cancer stem cells
(RIKEN) Scientists from the RIKEN Center for Integrative Medical Sciences in Japan and international collaborators have found that in humanized mice, a cocktail of drugs blocking certain key pathways is effective in eliminating acute myeloid leukemia (AML), a disease which is estimated to kill more than 250,000 people a year around the world. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: news

People with leukemia and their oncologists have vastly different perceptions of prognosis
(American Society of Clinical Oncology) A study of 100 people with acute myeloid leukemia (AML) receiving chemotherapy found that patient and physician perceptions of treatment risk and the likelihood of a cure varied widely. Overall, patients tended to overestimate both the risk of dying due to treatment and the likelihood of a cure. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2017 Category: Cancer & Oncology Source Type: news

Bolstering fat cells offers potential new leukemia treatment
(McMaster University) Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, says a study from McMaster University published in Nature Cell Biology. Researchers with the McMaster Stem Cell and Cancer Research Institute found that boosting adipocytes, or fat cells, located in the bone morrow suppressed cancerous leukemia cells but -- in a surprise to the research team -- also induced the regeneration of healthy blood cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 16, 2017 Category: Biology Source Type: news

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells
October 9, 2017—BRONX, NY—Scientists atAlbert Einstein College of Medicine have discovered the first compound that directly makescancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. (Source: Einstein News)
Source: Einstein News - October 9, 2017 Category: Universities & Medical Training Source Type: news

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells
October 9, 2017—BRONX, NY—Scientists atAlbert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue ofCancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. (Source: Einstein News)
Source: Einstein News - October 9, 2017 Category: Universities & Medical Training Source Type: news

Medical News Today: New compound kills cancer without harming healthy cells
A proof-of-concept study shows how a new compound selectively triggers cell suicide in acute myeloid leukemia cells without harming healthy cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 9, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Stealing from the body: How cancer recharges its batteries
(University of East Anglia) New research published today uncovers how the blood cancer 'steals' parts of surrounding healthy bone marrow cells to thrive, in work that could help form new approaches to cancer treatment in the future. Researchers at the University of East Anglia (UEA), funded by the Rosetrees Trust and The Big C Charity, found that healthy bone marrow stromal cells were made to transfer their power-generating mitochondria to neighbouring cancer cells, effectively 'recharging' the acute myeloid leukaemia (AML) and supporting the leukaemia to grow. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2017 Category: Cancer & Oncology Source Type: news

BioLineRx launches Phase Ib/II combination trial for acute myeloid leukaemia
Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech ’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news

HLA-mismatched Microtransplant Benefits Older AML Patients HLA-mismatched Microtransplant Benefits Older AML Patients
Most older patients with newly diagnosed acute myeloid leukemia (AML) achieve complete remission and good overall survival after HLA-mismatched microtransplant, according to results from 12 centers in China, the United States, and Spain.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Novartis's Rydapt wins EU approval for AML, other diseases
ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

Inhibitors support immune therapy for leukemia
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and T ü bingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Mylotarg to treat acute myeloid leukemia
The U.S. Food and Drug Administration approved Mylotarg, or gemtuzumab, for the treatment of adults with newly diagnosed acute myloid leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 5, 2017 Category: Consumer Health News Source Type: news

Pfizer ’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted approval to Pfizer ’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 3, 2017 Category: Pharmaceuticals Source Type: news